Aeglea BioTherapeutics, a company specializing in clinical-stage biotechnology, is making waves in the realm of rare metabolic disease treatment. They have developed groundbreaking human enzyme therapeutics, such as pegtarviliase and pegzilarginase, which are in Phase I/II and Phase III PEACE trials respectively. While pegtarviliase is designed to help patients with homocystinuria, pegzilarginase aims to provide a safe and effective treatment for people suffering from Arginase 1 deficiency. The company also boasts a promising preclinical pipeline, which includes AGLE-325 for the treatment of cystinuria and other research programs. Founded in 2013 and headquartered in Austin, Texas, Aeglea BioTherapeutics was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.